Compare GL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GL | DVA |
|---|---|---|
| Founded | 1900 | 1994 |
| Country | United States | United States |
| Employees | 3732 | N/A |
| Industry | Life Insurance | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.1B |
| IPO Year | N/A | 2002 |
| Metric | GL | DVA |
|---|---|---|
| Price | $138.71 | $156.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | ★ $166.18 | $156.75 |
| AVG Volume (30 Days) | 375.2K | ★ 738.3K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $9.74 | $3.85 |
| Revenue Next Year | $5.55 | $3.07 |
| P/E Ratio | ★ $10.21 | $15.77 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $109.38 | $101.00 |
| 52 Week High | $152.71 | $159.42 |
| Indicator | GL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 64.58 |
| Support Level | $135.08 | $146.05 |
| Resistance Level | $141.26 | $158.31 |
| Average True Range (ATR) | 2.52 | 3.93 |
| MACD | -0.26 | -0.50 |
| Stochastic Oscillator | 30.50 | 93.52 |
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.